Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03786107
Recruitment Status : Recruiting
First Posted : December 24, 2018
Last Update Posted : October 3, 2019
Sponsor:
Information provided by (Responsible Party):
Puma Biotechnology, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : January 15, 2024
Estimated Study Completion Date : January 15, 2024